What is the Dose-Response Curve?

Finding the optimum dose is imperative to drug discovery and development workflows. Dose-response curves are graphical representations that depict the relationship between a drug molecule's dose and the biological responses it generates. In these line charts, the X axis corresponds to the dose, while the Y axis indicates the magnitude of the response.

Defining the dose-response relationship

The dose-response relationship explains how varying the dose of a drug alters biological outcomes. The shape and critical points of the curve reveal valuable information regarding drug efficacy and safety.

Importance of dose-response curves in pharmacology

Researchers can estimate the minimum effective and maximum tolerated doses using dose-response curves, indicating efficacy and safety profiles. Furthermore, the shape of the curve uncovers the drug's mechanism of action and the factors influencing this mechanism, such as drug metabolism and receptor binding kinetics.

Importance of Dose-Response Curves

Dose-response curves are critical components of drug development pipelines, as their insights can guide regulatory documentation for efficacy and safety. This information can also be used to determine whether a small molecule is a suitable therapeutic option for a patient.

Key components of a dose-response analysis

The key concepts in dose-response analysis include the following:¹

1. Potency: The dose required to produce a therapeutic effect. The more potent a drug is, the lower the dose necessary to yield the same response.
2. Efficacy: The maximum therapeutic response a drug can produce. It is a different criterion from potency and often more significant. The more efficacious drugs will generate drug response curves with a greater height.
3. The slope of the dose-response curve determines how sensitive the response profile is to changes in drug concentrations.

Understanding EC50 and IC50 values

In high-throughput drug screening applications, reliable parameters are required to compare small-molecule drug candidates. Half-maximal effective (EC50 or Emax) and inhibitory concentrations (IC50) are often used as standard measures of potency.¹

EC50 refers to the concentration of a drug that produces half of its maximum effect. It is a standard measure of the potency of agonists, small molecules that activate their target proteins to initiate a biological response.¹

IC50 is the concentration of a substance that inhibits a specific biological process or response by 50%. It is widely used in characterizing antagonists or enzyme inhibitors, which interfere with a cellular process to attenuate disease progression.¹

Featured Product

Different Features of Dose-Response Curves

Besides the critical parameters, investigating the shape of dose-response curves is also crucial, as the shape can reveal the mechanism of action. It is important to note that the X-axis encompasses log values of the dose instead of absolute values to compress the wide range of concentrations, enabling a better visualization of the curve.¹

Characteristics of sigmoidal curves

Many drug molecules follow a sigmoidal dose-response curve that a classical Hill equation mathematical model can formulate.

Initially, the response increases exponentially with increasing dose until a point is reached, after which the impact of increasing the dose starts to decline and reaches a plateau. IC50 and EC50 values on a sigmoidal curve can be inferred from the X-axis value corresponding to the Y value at half the maximal response.¹

Exploring Multiphasic Features in Dose-Response Curves

Not all dose-response curves may be captured by the Hill equation, especially when they comprise multiple points of inflection or represent the combination of inhibitory and stimulatory effects.² To represent more complex drug mechanisms of action, Di Veroli and colleagues proposed a multiphasic model comprising multiple independent Hill equations, where each equation represents a separate biological phase, either inhibitory or stimulatory. Furthermore, they developed an automated fitting algorithm in their software Dr-Fit, which generated a set of multiphasic curves and ranked the best-fitting curve.³

The researchers tested their algorithm on 11,650 dose-response curves available on the Cancer Cell Line Encyclopedia (CCLE). While 72% of the curves could fit the monophasic (sigmoidal) model, the remaining 28% were more accurately modeled by multiphasic models with two inhibitory phases, stimulation followed by inhibition and three phases.³

Nonlinear responses in biological systems

Despite the advent of multiphasic models, many drugs may exhibit unpredictable dose-response curves. Several reasons may underlie the nonlinearity, such as a drug molecule acting on multiple receptors with different sensitivities, having dual effects (e.g., stimulatory at low doses and inhibitory at high doses) or metabolic saturation.⁴ These nonlinearities manifest as unexpected toxicity, low efficacy and drug resistance. Other fitting methods, such as piecewise polynomials (cubic spline), are used to tackle these complex dose-response relationships.⁵,⁶

Implications of Dose-Response in Risk Assessment

Dose-response curves are at the heart of risk assessment for not only drugs but also chemicals with potential hazards to humans and the environment. Therefore, regulatory agencies and pharmaceutical companies should possess the fundamental scientific knowledge to interpret dose-response curves and to guide decision-making when evaluating drugs or other substances.

Evaluating toxicity through dose-response relationships

In toxicology, dose-response curves are frequently used to assess the extent of harm caused by recreational substances or workplace hazards. Two key concepts are employed for safety assessment:⁷

1. No Observed Adverse Effect Level (NOAEL): the highest dose at which no harmful effect is seen
2. Lowest Observed Adverse Effect Level (LOAEL): the lowest dose where a harmful effect is observed

Regulators may place warnings or implement practices based on these values to determine hazard classification and safe exposure limits.⁷

Risk assessment in environmental science using dose-response

Environmental scientists can use dose-response curves to predict the effects of pollutants on ecosystems and human populations. Dose-response analysis reveals vital information, such as the threshold value for pesticide use before it affects the ecosystem.⁸ Therefore, it is commonly employed in the risk assessment models of many organizations, such as the European Food Safety Authority (EFSA).⁹

Regulatory considerations in drug concentration evaluations

Regulatory agencies, such as the FDA and EMA, must evaluate dose-response analysis to determine the therapeutic window, where a drug is effective but not toxic. The analysis informs whether the drug is approved and its dosing guidelines. Most importantly, dose-response curves help determine safety margins for vulnerable populations, including children, the elderly and pregnant women.¹⁰

How do Agonists and Antagonists Impact Dose-Response Curves?

Agonists and antagonists interact with receptors to activate or block their activity, respectively. These terms can refer to endogenous ligands and drug molecules designed to mimic these ligands or block their interactions. Probing their influence on dose-response curves may provide insight into a drug's interactions with endogenous ligands or other drugs, helping establish a balance between efficacy and safety.

Understanding the action of agonists in dose-response

An agonist mimics an endogenous ligand and binds its target receptor to trigger a biological response. The response increases with agonist concentration until reaching Emax. A prominent example is morphine, which mimics endogenous endorphins and acts on opioid receptors.¹¹

The impact of antagonists on drug efficacy

An antagonist blocks receptor activation and prevents the biological response elicited by the receptor. The impact of an antagonist on the dose-response curve depends on its binding mechanism. Introducing a competitive antagonist, which competes with the agonist for the binding site, to a receptor-agonist interaction shifts the curve to the right, as a higher agonist concentration is required to achieve the same biological response.¹² Naloxone is a competitive antagonist for opioid receptors. Naloxone is a competitive antagonist for opioid receptors, often used to reverse opioid overdose rapidly.¹³

Non-competitive agonists work differently by irreversibly binding the receptor and hindering its agonist-binding site. Thus, maximum response cannot be achieved despite increasing the concentration of the agonist. In other words, the dose-response curve not only shifts to the right but is also flattened, as Emax decreases.¹ Perampanel, used to treat tonic-clonic seizures, is a non-competitive antagonist for the glutamate receptor AMPA, which facilitates excitatory neurotransmission in the central nervous system.¹⁴

Comparative analysis of agonist and antagonist effects

Agonists and antagonists exhibit stimulatory and inhibitory effects on receptor activity and dose-response curves. Understanding the difference between agonists and antagonists on dose-response curves is imperative for designing effective treatment strategies to stimulate deficient pathways or inhibit receptor overactivation.

References

1. Maxwell SR. Pharmacodynamics and pharmacokinetics for the prescriber. Medicine 2024;52(1):1-10.
2. Conolly RB, Lutz WK. Nonmonotonic dose-response relationships: mechanistic basis, kinetic modeling, and implications for risk assessment. Toxicol Sci 2004;77(1):151-157.
3. Di Veroli GY, Fornari C, Goldlust I, Mills G, Koh SB, Bramhall JL, et al. An automated fitting procedure and software for dose-response curves with multiphasic features. Sci Rep 2015;5(1):14701.
4. Korchevskiy AA, Korchevskiy A. Non-linearity in cancer dose-response: The role of exposure duration. Comput Toxicol 2022;22:100217.
5. Li C, Wu W, Song Y, Xu S, Wu X. The nonlinear relationship between total bilirubin and coronary heart disease: a dose-response meta-analysis. Front Cardiovasc Med 2022;8:761520.
6. Zhao D, Liang Y, Dai S, Hou S, Liu Z, Liu M, et al. Dose-response effect of coenzyme Q10 supplementation on blood pressure among patients with cardiometabolic disorders: a grading of recommendations assessment, development, and evaluation (GRADE)-Assessed systematic review and meta-analysis of randomized controlled trials. Adv Nutr 2022;13(6):2180-2194.
7. Pizzo F, Gadaleta D, Benfenati E. In silico models for repeated-dose toxicity (RDT): Prediction of the no observed adverse effect level (NOAEL) and lowest observed adverse effect level (LOAEL) for drugs. In Silico Methods for Predicting Drug Toxicity: Springer; 2022:241-258.
8. Conley JM, Lambright CS, Evans N, Cardon M, Medlock-Kakaley E, Wilson VS, et al. A mixture of 15 phthalates and pesticides below individual chemical no observed adverse effect levels (NOAELs) produces reproductive tract malformations in the male rat. Environ Int 2021;156:106615.
9. Committee ES, More SJ, Bampidis V, Benford D, Bragard C, Halldorsson TI, et al. Guidance on the use of the benchmark dose approach in risk assessment. Efsa Journal 2022;20(10):e07584.
10. Moffett DB, Mumtaz MM, Sullivan Jr DW, Whittaker MH. General considerations of dose-effect and dose-response relationships. Handbook on the Toxicology of Metals: Elsevier; 2022:299-317.
11. Gopalakrishnan L, Chatterjee O, Ravishankar N, Suresh S, Raju R, Mahadevan A, et al. Opioid receptors signaling network. J Cell Commun Signal 2022;16(3):475-483.
12. Flynn SM, France CP. Discriminative stimulus effects of carfentanil in rats discriminating fentanyl: Differential antagonism by naltrexone. DAD 2021;221:108599.
13. Saari TI, Strang J, Dale O. Clinical pharmacokinetics and pharmacodynamics of naloxone. Clin Pharmacokinet 2024;63(4):397-422.
14. Perversi F, Costa C, Labate A, Lattanzi S, Liguori C, Maschio M, et al. The broad-spectrum activity of perampanel: state of the art and future perspective of AMPA antagonism beyond epilepsy. Front Neurol 2023;14:1182304.

recent-articles